Is Hodgkin’s Lymphoma Hereditary? A Look at Genetic Risk

Hodgkin lymphoma has a clear genetic component, but it is not hereditary in the way single-gene conditions are passed from parent to child. If a first-degree relative has been diagnosed, your own risk rises roughly threefold compared to the general population, yet the absolute likelihood of developing it remains low because Hodgkin lymphoma is uncommon to begin with. The genetics behind this elevated risk involve dozens of common gene variants, immune-system wiring, and interactions with environmental triggers like Epstein-Barr virus, making the hereditary picture far more layered than a simple yes-or-no answer suggests.

How Much Risk Runs in Families

The strongest population-level evidence comes from large Scandinavian registry studies that tracked cancer diagnoses across family trees. A pooled analysis of Swedish and Danish data found that relatives of Hodgkin lymphoma patients had about a threefold elevated risk of developing the disease themselves, with a combined relative risk of roughly 3.1.¹ A broader review of familial predisposition across lymphoma types reported a similar estimate, placing the risk increase for first-degree relatives at about 3.1-fold.² To put that in perspective, Hodgkin lymphoma affects roughly two to three people per 100,000 each year. A threefold increase pushes that to perhaps six to nine per 100,000, which is still a small number in absolute terms. Having a family member with the disease raises a flag on the risk radar without making the disease probable.

What Twin Studies Reveal

Twin research offers the sharpest lens for separating genetic from environmental influences because identical twins share virtually all their DNA while fraternal twins share about half. A landmark study of Scandinavian twin pairs found an enormous difference: among 179 pairs of identical twins where one had Hodgkin lymphoma, ten pairs eventually saw the second twin develop it too. Among 187 pairs of fraternal twins, that number was zero.³ The standardized incidence ratio for the identical co-twin was 99, meaning nearly a hundredfold increase over what would be expected in the general population. The complete absence of concordance in fraternal twins, who share both upbringing and roughly half their genes, points squarely to genetics rather than shared household exposures as the driving factor.

That said, “99-fold” does not mean the second twin was destined to develop lymphoma. Even in that study, most identical co-twins never developed the disease. The finding tells us that genetic makeup can profoundly raise susceptibility, but something beyond genes still has to go wrong for the cancer to actually appear.

Quantifying the Heritable Share

Researchers have tried to pin down how much of overall Hodgkin lymphoma risk can be chalked up to inherited DNA. A genome-wide analysis estimated that about 24 percent of the variation in classical Hodgkin lymphoma susceptibility is explained by common genetic variants across the genome.⁴ That figure captures only additive effects of common variants and doesn’t include rarer mutations, dominance effects, or gene-environment interplay. The known non-HLA risk variants discovered so far account for only about 12 percent of that heritable fraction, meaning most of the genetic architecture remains undiscovered. In practical terms, the disease sits in a middle zone: more heritable than many common cancers, but far from being determined by a single gene you either have or don’t.

The HLA Region and Immune Genes

The single most important genetic neighborhood for Hodgkin lymphoma risk is the HLA region on chromosome 6, which encodes proteins that help your immune system recognize threats. A large study of childhood Hodgkin lymphoma identified nearly 700 individual genetic variants in this region tied to disease risk, with the strongest signals clustering near genes called HLA-DRB1, HLA-DQA1, and HLA-DQB1.⁵ Some alleles increased risk, while others appeared protective, and dozens of amino acid changes in these HLA proteins were independently associated with susceptibility.

Beyond HLA, genome-wide association studies have identified risk loci scattered across several other chromosomes. A meta-analysis pinpointed significant associations at regions on chromosomes 3, 6, 10, 13, and 16, with many of the signals driven by the nodular sclerosis subtype of the disease.⁶ Each of these loci individually adds only a small nudge to risk. Their combined effect, layered on top of HLA variation, creates a spectrum of susceptibility rather than a binary on-or-off switch.

Epstein-Barr Virus Changes the Genetic Equation

One of the more striking findings in Hodgkin lymphoma genetics is that the specific gene variants that matter depend on whether the tumor is connected to Epstein-Barr virus. About a third of Hodgkin lymphoma cases in Western countries harbor EBV in the malignant cells, and the proportion is higher in other regions. Research has shown that HLA class I genes are associated with EBV-positive Hodgkin lymphoma specifically, while HLA class III variants are linked to EBV-negative cases.⁷ This distinction makes biological sense: class I molecules present viral fragments to killer T cells, so if your class I equipment handles EBV poorly, infected cells may be more likely to escape immune surveillance and become malignant.

Studies in different populations have borne this out. In Chinese patients, one particular HLA-A2 subtype (HLA-A*02:07) turned up at nearly double the frequency in EBV-positive cases compared to controls, while it appeared at less than half the control frequency in EBV-negative cases, acting as a risk factor for one and a protective factor for the other.⁸ More broadly, the HLA-A*02 allele has been identified as protective against EBV-related Hodgkin lymphoma.⁹ The upshot is that your genetic background shapes not just whether you’re susceptible to Hodgkin lymphoma, but which biological pathway might lead there.

The Hygiene Hypothesis and Early Immune Priming

Genetics and environment are difficult to separate in Hodgkin lymphoma. A pattern epidemiologists noticed decades ago is that young adults who grew up in smaller families, higher socioeconomic settings, and less crowded homes have higher rates of the disease. This fits a “hygiene hypothesis” model, in which limited microbial exposures early in life leave the immune system skewed in ways that may later contribute to lymphoma development. Research using twin pairs discordant for Hodgkin lymphoma found that the twin who had more oral exposures in early childhood was considerably less likely to develop the disease as a young adult.¹⁰

This connects back to genetics through immune signaling. A lower genetically determined interleukin-12 response has been identified as a risk factor for Hodgkin lymphoma, and a similar reduction in IL-12 can also result from reduced childhood exposure to environmental microbes.¹¹ In other words, certain people may carry genes that predispose them to a weaker immune priming response, and growing up in a cleaner environment can amplify the same vulnerability. The genetic susceptibility and the environmental trigger feed into each other, which partly explains why no single factor accounts for who gets Hodgkin lymphoma and who doesn’t.

Subtypes Carry Different Genetic Weight

Hodgkin lymphoma is not a single disease. The classical form, which accounts for the vast majority of cases, is itself subdivided into nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted types. A rarer entity called nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) behaves differently in the clinic and, it turns out, carries a much heavier familial burden. A Finnish registry study found that first-degree relatives of NLPHL patients had roughly a nineteenfold elevated risk of NLPHL themselves, far exceeding the threefold increase seen for classical Hodgkin lymphoma in the same dataset.¹²

At the molecular level, genomic sequencing has revealed that NLPHL and classical Hodgkin lymphoma share some mutations in pathways like JAK/STAT signaling and PD-L1/PD-L2 copy number gains, but diverge in others. NLPHL tumors carry recurrent mutations in genes such as JUNB, SOCS3, and IRF1 at rates significantly different from classical Hodgkin lymphoma.¹³ This genetic distinction matters because it suggests the familial predisposition to NLPHL may operate through different biological mechanisms than predisposition to classical Hodgkin lymphoma, and a family history of one doesn’t necessarily predict the other.

Rare Germline Mutations in Familial Cases

Most genetic risk for Hodgkin lymphoma comes from many common variants, each contributing a small amount. But in rare families where multiple siblings develop the disease at a young age, researchers have looked for single powerful mutations that might be driving the clustering. Exome sequencing of such families identified a homozygous deletion in a gene called ACAN (which encodes aggrecan, a protein better known for its role in cartilage) as a candidate for recessive Hodgkin lymphoma susceptibility. In these families, all affected siblings showed unusually high levels of homozygosity across their genomes, consistent with a recessive pattern of inheritance.¹⁴

Findings like these apply to a tiny fraction of cases. The vast majority of people who develop Hodgkin lymphoma, even those with a family history, will not carry a single high-penetrance mutation that explains their disease. But the existence of these rare variants confirms that the hereditary landscape of Hodgkin lymphoma spans a wide range, from common low-impact variants detectable by large association studies all the way to rare high-impact mutations found only in unusual pedigrees.

Autoimmune Disease as a Window Into Shared Susceptibility

One of the more unexpected pieces of the genetic puzzle is the overlap between autoimmune diseases and Hodgkin lymphoma. A large study tracking people with autoimmune conditions found that, overall, they had about twice the expected rate of Hodgkin lymphoma. Some specific conditions carried much higher risk: sarcoidosis elevated the rate about tenfold, systemic lupus erythematosus about eightfold, and rheumatoid arthritis about threefold.¹⁵ These associations held after accounting for timing, making simple surveillance bias an unlikely explanation.

Population-based case-control data from Scandinavia have specifically highlighted sarcoidosis, showing that both a personal and a family history of sarcoidosis are associated with higher Hodgkin lymphoma risk, pointing toward shared genetic susceptibility rather than one disease causing the other.¹⁶ Early research using polygenic risk scores has also explored whether inherited predispositions to specific immune conditions might cluster among Hodgkin lymphoma patients. One exploratory analysis in childhood cancer survivors found that a higher genetic loading for dermatitis was associated with roughly fivefold greater odds of Hodgkin lymphoma compared to other cancers, although the researchers noted these preliminary results need independent validation.¹⁷

The common thread is that Hodgkin lymphoma may be partly a disease of immune regulation gone wrong, and many of the genes that influence autoimmunity also influence lymphoma susceptibility. If you have a family history of autoimmune conditions, that shared immune wiring may matter more for Hodgkin lymphoma risk than the specific autoimmune diagnosis itself.

Does Family History Affect How the Disease Behaves

A reasonable worry for anyone with a family history is whether familial cases are more aggressive or harder to treat. The evidence here is reassuring. A study following lymphoma patients in Sweden found that five-year mortality for Hodgkin lymphoma was similar regardless of whether the patient had a family history of any lymphoma. The hazard ratio was 0.78, meaning familial cases trended slightly better, though the difference was not statistically significant.¹⁸ Having a relative with the same disease didn’t predict worse outcomes. This suggests that although genetic predisposition raises the chance of developing Hodgkin lymphoma, it doesn’t appear to make the resulting disease biologically worse or less responsive to standard treatment.

Epigenetic Differences Between Twins

Beyond the DNA sequence itself, researchers have started looking at epigenetic marks, chemical modifications that affect which genes are turned on or off without changing the underlying code. A study comparing long-term Hodgkin lymphoma survivors with their unaffected identical twins examined DNA methylation patterns in blood and saliva samples. While the study was designed to explore whether immune dysregulation leaves a lasting epigenetic footprint, the design itself highlights an important concept: two people can share the same genome and still differ in disease outcome because of how their genes are regulated over a lifetime.¹⁹

Epigenetic research in Hodgkin lymphoma is still in its early stages. But the existence of discordant identical twins, the majority, in fact, even in the studies showing high concordance, is itself proof that inherited DNA is necessary but not sufficient. Something in the environment, the timing of infections, immune challenges, or random biological noise tips some genetically susceptible people toward disease while sparing others with the same blueprint.

What This Means If Hodgkin Lymphoma Runs in Your Family

There is no clinical genetic test you can order today that will tell you whether you will develop Hodgkin lymphoma. The risk variants identified so far are common in the population, individually weak, and spread across many genes. Polygenic risk scores are being developed in research settings, but they are not yet validated enough for clinical decision-making. Genetic counselors familiar with lymphoma predisposition can help families with unusual clustering, particularly those with multiple affected relatives diagnosed young, evaluate whether further workup is warranted. For most people, though, a single affected relative means modest elevation in risk rather than a looming diagnosis.

Standard screening recommendations do not change for family members of Hodgkin lymphoma patients the way they might for, say, relatives of someone with a BRCA1-linked breast cancer. The disease is too uncommon and the genetic variants too diffuse for population-level screening to make sense. Being aware of symptoms like unexplained lymph node swelling, persistent fevers, drenching night sweats, and unintended weight loss is sensible for anyone, but it carries slightly more practical value if Hodgkin lymphoma has appeared in your family tree. Early detection remains the most meaningful advantage, and the good news is that Hodgkin lymphoma is among the most curable cancers even when caught at advanced stages.